Sugi Predict

Sugi Predict / Compounds / SCHEMBL182827

SCHEMBL182827

SCHEMBL182827

CCOc1cc[c]cc1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ TSHR P16473 1/20 0.42
▸ MAPK1 P28482 1/20 0.41
▸ CALM1 P0DP23 3/20 0.40
▸ PDE4A P27815 4/20 0.37
▸ PDE4B Q07343 4/20 0.37
▸ PDE4C Q08493 4/20 0.37
▸ PDE4D Q08499 4/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ ALDH1A1 P00352 3/20 0.36
▸ HPGD P15428 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ RECQL P46063 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ L3MBTL1 Q9Y468 3/20 0.36
▸ LMNA P02545 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL159256 0.92 KDM4E (0.42) MAPTKDM4EGAATSHRMAPK1
SCHEMBL127280 0.90 ALDH1A1 (0.39) MAPTKDM4EGAATSHRMAPK1
SCHEMBL8408770 0.85 KDM4E (0.34) MAPTKDM4EGAATSHRMAPK1
SCHEMBL542448 0.85 KDM4E (0.40) MAPTKDM4EGAATSHRSMN1; SMN2
SCHEMBL2462595 0.84 L3MBTL1 (0.41) MAPTKDM4EMAPK1SMN1; SMN2ALDH1A1
SCHEMBL7180376 0.83 CYP1A2 (0.41) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL8674 0.83 CA2 (0.46) MAPTKDM4ETSHRMAPK1PDE4A
SCHEMBL2459479 0.82 L3MBTL1 (0.42) MAPTKDM4EGAAALDH1A1HPGD
SCHEMBL27879858 0.82 CA2 (0.37) TSHRMAPK1PDE4APDE4BPDE4C
SCHEMBL182689 0.81 FDPS (0.39) MAPTMAPK1SMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174603-A1 MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME RAPPTA THERAPEUTICS OY (FI) 2024-05-30 — — US claimed
EP-4288412-A1 MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME Rappta Therapeutics Oy (FI) 2023-12-13 — — EP claimed
US-10329249-B1 Sulindac derivatives KING SAUD UNIVERSITY (SA) 2019-06-25 — — US claimed
EP-3123864-A1 IMIDAZOPYRAZINE SYK INHIBITORS Gilead Connecticut, Inc. (US) 2017-02-01 — — EP claimed
EP-2373169-B1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT INC (US) 2015-05-20 — — EP claimed
US-20140336169-A1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2014-11-13 — — US claimed
US-8748607-B2 Imidazopyrizine syk inhibitors GILEAD CONNECTICUT, INC. (US) 2014-06-10 — — US claimed
US-20130267496-A1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2013-10-10 — — US claimed
US-20130237520-A1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2013-09-12 — — US claimed
US-20130237521-A1 IMIDAZOPYRIZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2013-09-12 — — US claimed
WO-2008052733-A1 IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-05-08 — — WO claimed
WO-2008016682-A2 ARYL VINYL SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2008-02-07 — — WO claimed
WO-2008012326-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-31 — — WO claimed
EP-1212311-B1 CHALCONE COUMARINS INDENA SPA (IT) 2003-03-26 — — EP claimed
US-6395730-B1 CARDIOVASCULAR DISORDERS ICAGEN, INC. 2002-05-28 — — US claimed
EP-1082315-A1 POTASSIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2001-03-14 — — EP claimed
CN-1252070-A 5,7-disubstituted 4-aminopyrido [2,3,-d] pyrimidine compounds and their use as adenosine kinase inhibitors ABBOTT LAB (US) 2000-05-03 — — CN claimed
CN-1252069-A 5,6, 7-trisubstituted-4-aminopyrido [2, 3-d ] pyrimidine compounds ABBOTT LAB (US) 2000-05-03 — — CN claimed
WO-1999062891-A1 POTASSIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 1999-12-09 — — WO claimed
US-5231105-A Ethylamine derivatives and antihypertensives containing the same AJINOMOTO CO., INC. (JP) 1993-07-27 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237520-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 MAPT 3775/4885KDM4E 1611/4885GAA 545/4885
US-10329249-B1 Sulindac derivatives SI, HRH2, SULT2A1 MAPT 3365/4885KDM4E 3477/4885GAA 662/4885
US-20240174603-A1 MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME PPM1A, PPP2CA, PPP3CA MAPT 927/4885KDM4E 2199/4885GAA 1615/4885
US-20140336169-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 MAPT 3775/4885KDM4E 1611/4885GAA 545/4885
US-20130267496-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 MAPT 3775/4885KDM4E 1611/4885GAA 545/4885
US-20130237521-A1 IMIDAZOPYRIZINE SYK INHIBITORS SYK, ZAP70, BTK MAPT 3847/4885KDM4E 1470/4885GAA 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.